Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)
- First Posted Date
- 2013-01-21
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1487
- Registration Number
- NCT01772472
- Locations
- 🇺🇸
Kaiser Permanente - Vallejo, Vallejo, California, United States
🇺🇸The Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸Kaiser Permanente - San Diego, San Diego, California, United States
A Long-Term Extension Study of WA22763 and NA25220 of Subcutaneous RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis
- First Posted Date
- 2013-01-21
- Last Posted Date
- 2016-11-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 47
- Registration Number
- NCT01772316
A Prospective, Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2013-01-18
- Last Posted Date
- 2018-03-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 100
- Registration Number
- NCT01770834
A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Participants
- First Posted Date
- 2013-01-14
- Last Posted Date
- 2018-02-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 8
- Registration Number
- NCT01767623
- Locations
- 🇺🇸
California Cancer Associates for Research & Excellence, Inc., Encinitas, California, United States
🇬🇧Velindre Cancer Centre, Cardiff, United Kingdom
🇦🇺Peninsula and South Eastern Haematology and Oncology Grou, Frankston, Victoria, Australia
A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma
- First Posted Date
- 2013-01-10
- Last Posted Date
- 2015-09-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 29
- Registration Number
- NCT01765569
Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer
- Conditions
- Colorectal Neoplasms
- Interventions
- First Posted Date
- 2013-01-10
- Last Posted Date
- 2017-09-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 280
- Registration Number
- NCT01765582
- Locations
- 🇺🇸
USC Norris Cancer Center, Los Angeles, California, United States
🇺🇸Johns Hopkins Univ; Bunting Blaustein Cancer Center, Baltimore, Maryland, United States
🇺🇸Tufts Medical Center, Boston, Massachusetts, United States
A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)
- First Posted Date
- 2013-01-10
- Last Posted Date
- 2016-12-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 27
- Registration Number
- NCT01765543
A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma
- Conditions
- Malignant Melanoma, Neoplasms
- Interventions
- First Posted Date
- 2013-01-10
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT01765556
A Study to Assess Hemoglobin Level Depending on the Comorbidity Index in Chronic Kidney Disease (CKD) Participants Not in Dialysis Treated With Methoxy Polyethylene Glycol-Epoetin Beta (COMETE)
- Conditions
- Renal Anemia of Chronic Kidney Disease
- Interventions
- First Posted Date
- 2012-12-27
- Last Posted Date
- 2019-07-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 551
- Registration Number
- NCT01756612
- Locations
- 🇫🇷
Hopital Claude Huriez; Nephrologie, Lille, France
🇫🇷Ctre Hosp St Joseph Et St Luc; Nephrologie Hemodialyse, Lyon, France
🇫🇷Polyclinique De La Louviere; Nephrologie, Lille, France
An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1
- Conditions
- Hepatitis C, Chronic
- First Posted Date
- 2012-12-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 196
- Registration Number
- NCT01750216